Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer
June 01 2021 - 7:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing a new modality of orally delivered
medicines, today announced the appointment of Mark Plinio as Chief
Commercial Officer, effective June 14, 2021. Mr. Plinio brings
significant pharmaceutical sales and marketing leadership to Evelo,
including experience building and managing blockbuster brands
through all stages of commercialization.
“We are pleased to welcome Mark to Evelo as we look forward to
key milestones across our broad portfolio of SINTAX medicines, and
continue building our team for the future,” said Simba Gill, Ph.D.,
Chief Executive Officer of Evelo. “Mark’s leadership and broad
experience launching blockbuster products will be essential as we
build the late-stage development and commercial capabilities needed
to become a multi-product company delivering on the full promise of
our therapies to patients around the world.”
Mr. Plinio joins Evelo from Ironwood Pharmaceuticals, where he
served as Chief Commercial Officer and Senior Vice President,
Marketing and Sales, and was responsible for managing the
development and execution of U.S. and global commercial strategic
plans to advance the Company’s gastroenterology-focused portfolio.
Prior to joining Ironwood, Mr. Plinio spent nearly two decades at
Novartis Pharmaceuticals in roles of increasing responsibility in
Legal, Marketing, and Sales, including serving as Head of
Dermatology and Rheumatology Marketing, Cosentyx®. In this role, he
led the strategy, planning, and all aspects of brand management for
the launch of Cosentyx, which was recognized as one of the most
successful launches in Novartis’s history. Prior to Novartis, Mr.
Plinio worked as an associate attorney at Skadden, Arps, Slate,
Meagher & Flom, LLP and at Mudge, Rose, Guthrie, Alexander
& Ferdon, LLP. He holds his J.D. from Seton Hall University
School of Law and his B.A. in Economics and Legal Studies from
Bucknell University.
“Evelo’s portfolio has the potential to transform patient care
by providing a new type of medicine that is safe, effective,
convenient, and affordable for millions of people,” said Mr.
Plinio. “From my experience launching drugs for inflammatory
diseases, there is a significant unmet need in the mild and
moderate patient population – and EveIo is looking to bridge that
treatment gap. As EDP1815 continues to progress through development
for the treatment of psoriasis and atopic dermatitis, now is the
time to begin building an integrated, nimble commercial
organization. I look forward to working with the strong Leadership
Team at Evelo, leveraging my deep knowledge to complement the great
work already in motion, in order to capture the full breadth and
impact of SINTAX medicines.”
About Evelo BiosciencesEvelo Biosciences is a
clinical stage biotechnology company developing orally delivered
medicines that act on SINTAX™, the small intestinal axis, to have
systemic therapeutic effects. SINTAX plays a central role in
governing the immune, metabolic, and neurological systems.
Evelo currently has four product candidates in development:
EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory
diseases and EDP1908 for the treatment of cancer. Evelo is
advancing additional product candidates in other disease
areas.
For more information, please visit www.evelobio.com and
engage with Evelo on LinkedIn.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including statements concerning our development plans and the
promise and potential impact of our product candidates.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties, and
other important factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, the following: the impact of the COVID-19 pandemic on
our operations, including our preclinical studies and clinical
trials, and the continuity of our business; we have incurred
significant losses, are not currently profitable and may never
become profitable; our need for additional funding; our limited
operating history; our unproven approach to therapeutic
intervention; the lengthy, expensive, and uncertain process of
clinical drug development, including potential delays in regulatory
approval; our reliance on third parties and collaborators to expand
our microbial library, conduct our clinical trials, manufacture our
product candidates, and develop and commercialize our product
candidates, if approved; our lack of experience in manufacturing,
selling, marketing, and distributing our product candidates;
failure to compete successfully against other drug companies;
protection of our proprietary technology and the confidentiality of
our trade secrets; potential lawsuits for, or claims of,
infringement of third-party intellectual property or challenges to
the ownership of our intellectual property; our patents being found
invalid or unenforceable; risks associated with international
operations; our ability to retain key personnel and to manage our
growth; the potential volatility of our common stock; our
management and principal stockholders have the ability to control
or significantly influence our business; costs and resources of
operating as a public company; unfavorable or no analyst research
or reports; and securities class action litigation against us.
These and other important factors discussed under the caption
"Risk Factors" in our Quarterly Report on Form 10-Q for the three
months ended March 31, 2021 and our other reports filed with the
SEC could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, except as required by law, we disclaim any obligation to do
so, even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
ContactJessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024